Sharlene Gill: Adjuvant immunotherapy in patients with resected ESO/GEJ cancer
Sharlene Gill, Medical Oncologist and Medical Director, Staff Wellness and Engagement at BC Cancer, shared a post on X about a recent paper by her and Tim Lee, published in ESMO Gastrointestinal Oncology:
“Happy to share our RWE BC Cancer recent publication.
CM577 – 1 year of adjuvant Nivolumab is an important advance for resected – esophagogastric cancers and grateful to be able to offer this to our patients.
…an additional 4-5 hours of oncologist direct care work is generated per patient treated.
An overwhelming majority of Canadian MedOncs are not fee-for-service…so this use is an ‘add-on’.
When we think of cost and system capacity, should we also plan to resource oncologist workload capacity for new indications?”
Authors: Sharlene Gill and Tim Lee
Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver, Canada. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and Chair of the UBC Department of Medicine Mentoring Committee.
She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists. Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.
More posts featuring Sharlene Gill.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023